200 related articles for article (PubMed ID: 37110590)
21. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
[TBL] [Abstract][Full Text] [Related]
22. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
[TBL] [Abstract][Full Text] [Related]
23. Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
Pulido R; Nunes-Xavier CE
Transl Oncol; 2023 Jan; 27():101580. PubMed ID: 36327699
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.
Bottino C; Vitale C; Dondero A; Castriconi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444389
[TBL] [Abstract][Full Text] [Related]
25. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
26. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract][Full Text] [Related]
27. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract][Full Text] [Related]
28. ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
Shin SH; Ju EJ; Park J; Ko EJ; Kwon MR; Lee HW; Son GW; Park YY; Kim YJ; Song SY; Lee S; Seo BS; Song JA; Lim S; Jung D; Kim S; Lee H; Park SS; Jeong SY; Choi EK
Cancer Cell Int; 2023 Aug; 23(1):172. PubMed ID: 37596639
[TBL] [Abstract][Full Text] [Related]
29. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
Xu H; Cheung IY; Guo HF; Cheung NK
Cancer Res; 2009 Aug; 69(15):6275-81. PubMed ID: 19584290
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma.
Tang M; Chen C; Wang G; Wang Y; Zhang Z; Li H; Lu Q; Wang Z; Zhao S; Yang C; Zhong K; Zhang R; Guo L; Yuan Z; Nie C; Tong A
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551172
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
34. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
35. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
36. B7-H3-Targeting Chimeric Antigen Receptors Epstein Barr Virus Specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3 Positive Solid Tumors.
Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
Cancer Res Commun; 2024 May; ():. PubMed ID: 38717140
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
38. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
[TBL] [Abstract][Full Text] [Related]
39. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]